Details of the Drug

General Information of Drug (ID: DMO8D4V)

Drug Name
AdoC(beta-Ala)Arg6
Synonyms CHEMBL611122
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1289.4
Topological Polar Surface Area (xlogp) -11.1
Rotatable Bond Count (rotbonds) 41
Hydrogen Bond Donor Count (hbonddonor) 23
Hydrogen Bond Acceptor Count (hbondacc) 22
Chemical Identifiers
Formula
C49H88N30O12
IUPAC Name
(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
Canonical SMILES
C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
InChI
InChI=1S/C49H88N30O12/c50-34-30-35(71-21-70-34)79(22-72-30)42-32(82)31(81)33(91-42)41(88)63-20-13-29(80)73-23(7-1-14-64-44(51)52)36(83)74-24(8-2-15-65-45(53)54)37(84)75-25(9-3-16-66-46(55)56)38(85)76-26(10-4-17-67-47(57)58)39(86)77-27(11-5-18-68-48(59)60)40(87)78-28(43(89)90)12-6-19-69-49(61)62/h21-28,31-33,42,81-82H,1-20H2,(H,63,88)(H,73,80)(H,74,83)(H,75,84)(H,76,85)(H,77,86)(H,78,87)(H,89,90)(H2,50,70,71)(H4,51,52,64)(H4,53,54,65)(H4,55,56,66)(H4,57,58,67)(H4,59,60,68)(H4,61,62,69)/t23-,24-,25-,26-,27-,28-,31+,32-,33+,42?/m1/s1
InChIKey
SKHJPFQNPQEHHQ-VOMWTDLXSA-N
Cross-matching ID
PubChem CID
46877397
TTD ID
D0V3TE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
cAMP protein kinase type II-beta (PRKAR2B) TTW4Y2M KAP3_HUMAN Inhibitor [1]
cAMP-dependent protein kinase A type I (PRKAR1A) TTNAHEX KAP0_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
2 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
5 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
6 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
7 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.